Andrew Wiznia, MD

Jacobi Medical Center, Albert Einstein College of Medicine
Bronx, New York, United States

Disclosure(s): Gilead Sciences, Inc.: Advisor/Consultant; Janssen: Advisor/Consultant

Presentation(s):

• 155 - Long-Acting Subcutaneous Lenacapavir in People with Multi-Drug Resistant HIV-1: 3-Year Results of the CAPELLA Study

  Thursday, October 17, 2024
  2:00 PM – 2:15 PM US PT